SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sunesis Pharmaceuticals, Inc. – SNSS
NEW YORK, NY / CRWEPRESSRELEASE / July 23, 2015 / Pomerantz LLP is investigating claims on behalf of investors of Sunesis Pharmaceuticals, Inc. (“SNSS” or the “Company”) (NASDAQ: SNSS). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether Sunesis and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On July 23, 2015, post-market, Sunesis announced that the FDA had informed the company that more clinical evidence demonstrating the efficacy of vosaroxin, the company’s proposed leukemia treatment, was needed before the agency would consider a new drug application (NDA) submission.
On this news, the company’s stock fell 56% on heavy after-hours trading on July 23, 2015.
The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.